Page 44 - Morphosys All The Shares News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosys all the shares. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosys All The Shares Today - Breaking & Trending Today

MorphoSys AG: MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab


(2)
PLANEGG/MUNICH, GERMANY and MONTREAL, QC / ACCESSWIRE / January 12, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplant (ASCT).
With the acceptance of the NDS by Health Canada, review of the data can begin, an important step on the path to making tafasitamab available in Canada for use in combination with lenalidomide in eligible patients with relapsed or refractory DLBCL, said Josée Brisebois, Ph.D., Head of Medical Affairs, Incyte Biosciences Canada. We intend to ....

United States , Julia Neugebauer , Myles Clouston , Jeanette Bressi , Thomas Biegi , Catalina Loveman , Michael Booth , Nuwan Kurukulasuriya , Christine Chiou , Global Medical Affairs , Practice Research Clinical Haematology , Janssen Biotech Inc , Xencor Inc , Drug Administration , Janssen Research Development , Morphosys Us Inc , Head Of Medical Affairs Incyte Biosciences Canada , Exchange Commission , Us Communications , Public Affairs , Health Canada , Prime Standard Segment , New Drug Submission , Medical Affairs , Incyte Biosciences , Senior Vice President Global Medical Affairs ,